The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
4 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,081,237 in first-year total cost, median $669,747.
Most frequent study sections
- Special Emphasis Panel[ZRG1 ETTN-G (12)]1
- Special Emphasis Panel[ZRG1 ETTN-S (14)]1
- Special Emphasis Panel[ZRG1 OTC-L (12)]1
- Special Emphasis Panel[ZRG1 SBIB-T (10)]1
Most frequent institutions
- CADENZAMED, LLC1
- CIRCUMVENT PHARMACEUTICALS, INC.1
- CYNVEC, LLC1
- EYEMEDIX, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL)1R44NS120360-01A1 | STEINER, ROBERT DAVIDWILEY, DEVIN THOMAS | CIRCUMVENT PHARMACEUTICALS, INC., CA | $1,441,757 | ZRG1 |
| 2020 | A novel and effective immunotherapeutic approach for tumors with a low mutational load and few tumor-infiltrating lymphocytes, such as ovarian cancer1R44CA250627-01 | MERUELO, DANIELSESSIONS, JENNIFER JUNE | CYNVEC, LLC, NY | $400,000 | ZRG1 |
| 2020 | A Novel PET Imaging based Companion Diagnostic1R43CA246853-01A1 | SARKAR, SUSANTA K | CADENZAMED, LLC, PA | $299,987 | ZRG1 |
| 2019 | Development of a biomimetic small molecule therapeutic for neovascular retinal diseases2R44EY025490-02A1 | WANG, AMY | EYEMEDIX, INC., CA | $939,493 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.